Nitrazepam Accord (Nitrazepam)

Nitrazepam acts as a positive allosteric modulator at the GABA‑A receptor. By binding to a specific site, it increases the frequency of chloride channel opening when GABA binds, enhancing inhibitory neurotransmission and producing sedative, anxiolytic, muscle‑relaxant, and anticonvulsant effects.

The prescribed dose of nitrazepam is individualized by the treating clinician based on the patient’s age, clinical condition, response, and any comorbidities. Healthcare professionals determine the appropriate strength and dosing schedule, which may differ for insomnia versus anxiety management.

Safety data for nitrazepam in pregnancy and lactation are limited, and the medication is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Nitrazepam Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nitrazepam shares the core mechanism of GABA‑A modulation with other benzodiazepines but is distinguished by a relatively long half‑life, which can provide sustained sleep promotion. Compared with shorter‑acting agents, it may have a higher risk of next‑day sedation, making patient selection and dosing duration important considerations.

Nitrazepam Accord should be stored at room temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Nitrazepam Accord is administered orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at bedtime for insomnia or as directed by a physician for anxiety. It should not be crushed, chewed, or divided unless specifically advised.

Serious risks include severe depression or suicidal thoughts, respiratory depression especially when combined with other depressants, paradoxical reactions such as agitation, and rare but severe skin reactions. Patients should seek immediate medical attention if they experience any of these symptoms.

Nitrazepam is contraindicated in individuals with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients with a history of severe hepatic impairment. Caution is also advised for the elderly, pregnant or nursing women, and those with a history of substance dependence.